Journal of Oncology / 2009 / Article / Tab 1 / Review Article
Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors Table 1 EGFR-targeted therapies in clinical development for SCCHN.
Agent Sponsor Class FDA-approval Clinical trial phase for SCCHN Antibodies Cetuximab C225, Erbitux ImClone Systems Chimeric IgG1 SCCHN; colorectal cancers III Nimotuzumab h-R3 YM Biosciences Humanized IgG1 — IV Advanced disease; II Locally advanced disease Panitumumab ABX-EGF; Vectibix Amgen Fully human IgG2 Colorectal cancers III Zalutumumab HuMax-EGFR GenMab Fully human IgG1 — III Tyrosine kinase inhibitors Erlotinib Tarceva; OSI-774 Genetech and OSI Pharmaceuticals Reversible ATP competive Lung cancer III Gefitinib ZD-1839; Iressa AstraZeneca Reversible ATP competive Lung cancer, relabeling limits III Lapatinib Tykerb GlaxoSmithKline Reversible ATP competitive dual EGFR/Her2 Breast cancer III Zactima ZD6474 AstraZeneca Reversible ATP competitive VEGFR-2, EGFR and RET — II